Participate in Research at CU Anschutz

Given the negative symptoms associated with cancer, palliative care, a broad term for the prevention and treatment of adverse effects that arise from a disease or its treatment, continues to be a focus of cancer related research. In recent years one of the most popular options for this has become cannabis. There has been in increase of cancer patients using cannabis for relief; specifically, to improve sleep problems, decrease pain, and cope with stress. However, variation in recreationally available products makes determining the efficacy of different cannabinoids like CBD and THC difficult, this has lead to a lack of clear recommendations for those seeking relief. As such, this study aims to examine the therapeutic benefits of cannabis through a rigorous placebo-controlled design. Study participants will be assigned to take one of three medications over the course of 8 weeks: a CBD only product, a CBD product that contains a small amount of THC, or a Hemp Seed Oil product that does not contain either. These products are a Food and Drug Administration (FDA) Investigational New Drug (IND).

This study involves a total of 4 visits over the course of 8 weeks. Most of the appointments will be conducted solely out of the Anschutz Health Sciences Building (AHSB) except for appointment 3; this appointment will start at your home in our mobile and will finish at AHSB. At each appointment you will complete blood draws, other physical measures, cognitive tasks, as well as survey questions about your health, thoughts and lifestyle. At the third appointment you will use your study medication.